Sieber Martin A, Pietsch Hubertus, Walter Jakob, Haider Wolfram, Frenzel Thomas, Weinmann Hanns-Joachim
Bayer Schering Pharma AG, Berlin, Germany.
Invest Radiol. 2008 Jan;43(1):65-75. doi: 10.1097/RLI.0b013e31815e6277.
Several recent publications have suggested an association between the administration of gadolinium (Gd)-based contrast agents and the occurrence of Nephrogenic Systemic Fibrosis (NSF), an acquired disorder marked by skin thickening and fibrosis occurring in patients with severe renal dysfunction. The aim of this study was to establish a preclinical experimental setting to investigate the possible link between NSF and Gd-based contrast agents, and specifically the role of Gd and/or depletion of endogenous metal ions as possible triggers for NSF.
Thirty-five healthy male rats received repeated intravenous injections of Magnevist (gadopentetate dimeglumine; Gd-DTPA), Omniscan (gadodiamide; Gd-DTPA-BMA), or gadodiamide without caldiamide at a dose of 2.5 mmol Gd/kg body weight over at least 20 days to simulate the exposure to Gd-containing contrast agents in patients with severe renal dysfunction. In addition, caldiamide (the excess ligand in Omniscan) and Gd-ethylenediamine tetraacetic acid (Gd-EDTA) as a positive control, and saline as a negative control were studied. Histopathologic and immunohistochemical analysis of the skin was performed. Gd and zinc concentrations were measured in skin, femur, and liver tissue by atomic emission spectrometry.
Rats receiving Gd-EDTA, gadodiamide without caldiamide, and Omniscan developed epidermal ulceration and acanthosis, dermo-epidermal clefts, minimal-to-slight dermal fibrosis, and increased dermal infiltration of different cells, partly positive for CD34 fibrocytes. No such NSF-like macroscopic lesions were observed in the saline, caldiamide, and Magnevist groups. High Gd concentrations in the skin were found in the Gd-EDTA, gadodiamide without caldiamide, and Omniscan groups. In the Magnevist group, Gd levels in the skin were 10-times lower than in the Omniscan-treated animals but elevated compared with saline.
A preclinical experimental setting has been established where NSF-like lesions could be observed. The link between the application of Gd-based contrast media and the induction of NSF-like lesions was established. The data indicate that the observed skin lesions are related to the release of Gd and not to the depletion of endogenous ions. The investigations further suggest potential importance of the stability of Gd-based contrast agents.
最近的几篇出版物表明,钆(Gd)基造影剂的使用与肾源性系统性纤维化(NSF)的发生之间存在关联,NSF是一种后天性疾病,表现为严重肾功能不全患者出现皮肤增厚和纤维化。本研究的目的是建立一个临床前实验环境,以研究NSF与Gd基造影剂之间的可能联系,特别是Gd和/或内源性金属离子耗竭作为NSF可能触发因素的作用。
35只健康雄性大鼠接受重复静脉注射马根维显(钆喷酸葡胺;Gd-DTPA)、欧乃影(钆双胺;Gd-DTPA-BMA)或不含卡地胺的钆双胺,剂量为2.5 mmol Gd/kg体重,至少持续20天,以模拟严重肾功能不全患者接触含Gd造影剂的情况。此外,还研究了卡地胺(欧乃影中的过量配体)和钆乙二胺四乙酸(Gd-EDTA)作为阳性对照,以及生理盐水作为阴性对照。对皮肤进行了组织病理学和免疫组织化学分析。通过原子发射光谱法测量皮肤、股骨和肝脏组织中的Gd和锌浓度。
接受Gd-EDTA、不含卡地胺的钆双胺和欧乃影的大鼠出现表皮溃疡和棘皮症、真皮表皮裂隙、轻微至轻度真皮纤维化,以及不同细胞的真皮浸润增加,部分CD34纤维细胞呈阳性。在生理盐水、卡地胺和马根维显组中未观察到此类NSF样宏观病变。在Gd-EDTA、不含卡地胺的钆双胺和欧乃影组中发现皮肤中Gd浓度较高。在马根维显组中,皮肤中的Gd水平比接受欧乃影治疗的动物低10倍,但与生理盐水相比有所升高。
已建立一个临床前实验环境,在该环境中可观察到NSF样病变。建立了Gd基造影剂的应用与NSF样病变诱导之间的联系。数据表明,观察到的皮肤病变与Gd的释放有关,而与内源性离子的耗竭无关。研究进一步表明了Gd基造影剂稳定性的潜在重要性。